New Jersey Administrative Code
Title 10 - HUMAN SERVICES
Chapter 161B - STANDARDS FOR LICENSURE OF OUTPATIENT SUBSTANCE USE DISORDER TREATMENT FACILITIES
Subchapter 11 - OPIOID TREATMENT SERVICES
Section 10:161B-11.9 - Drug screening
Current through Register Vol. 56, No. 18, September 16, 2024
(a) Random drug screening shall be conducted on varied days and weeks of the month to detect, at a minimum, the presence of opioids, methadone, cocaine, amphetamines, and benzodiazapenes. Screening for alcohol, marijuana and other drugs shall be conducted based on individual and/or community drug use patterns in accordance with program policy established by the multidisciplinary team.
(b) Random drug screening to identify continued drug abuse shall be conducted every two weeks until the client has maintained drug-free screening results for three consecutive months, after which time random drug screening shall be performed at least monthly. A positive drug screening for drugs other than methadone during any phase of treatment shall require resumption of a sampling schedule as determined by the multi-disciplinary team. The opioid treatment program shall respond to continuing positive drug screening results for drugs other than methadone by documentation in the client's chart of more intensive treatment interventions, or referral to another treatment provider including residential treatment.
(c) Clients in clinic based medical maintenance, Phase VI, shall receive monthly drug screening and an additional two special call backs in the first year with subsequent call backs as delineated by program policy for determining client responsibility in handling extended take-homes and drug screening at the time of the special call backs.
(d) Prescription drug use identified by drug screening shall be considered a positive drug screening result if the client: has not provided documentation from the prescribing physician that the client is under care for a diagnosed medical condition; refuses to sign a release authorizing the opioid treatment program to contact the prescribing physician; or has not documented to the opioid treatment program that the physician is aware that the client is on methadone. Such documentation shall be reviewed and approved in writing by the medical director or opioid treatment program physician.
(e) Client acknowledgement of drug use shall void the necessity of drug testing, shall be considered a positive drug screening, and shall result in appropriate actions as described above.
